Interpretation of "International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn".
10.7499/j.issn.1008-8830.2205158
- Author:
Fang-Jun HUANG
1
;
Yang HE
1
;
Jun TANG
1
;
Meng ZHANG
1
;
Jian CHEN
;
De-Zhi MU
1
Author Information
1. Department of Pediatrics, West China Second Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China.
- Publication Type:Journal Article
- Keywords:
Haemolytic disease of the newborn;
International guideline;
Intravenous immunoglobulin;
Neonate
- MeSH:
Infant, Newborn;
Female;
Humans;
Immunoglobulins, Intravenous/therapeutic use*;
Erythroblastosis, Fetal/drug therapy*;
Exchange Transfusion, Whole Blood;
Hematologic Diseases;
Hyperbilirubinemia
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(11):1183-1188
- CountryChina
- Language:Chinese
-
Abstract:
International guidelines regarding the role of intravenous immunoglobulin (IVIG) in the management of Rh- and ABO-mediated haemolytic disease of the newborn was drafted by an international panel of experts in the fields of hematology, neonatology, and blood transfusion and was published in British Journal of Haematology on March 16, 2022. The guidelines summarize the evidence-based practice of IVIG in Rh- and ABO-mediated haemolytic disease of the newborn and propose related recommendations. The guidelines recommend that IVIG should not be applied as a routine treatment regimen for Rh- and ABO-mediated haemolytic disease of the newborn in order to reduce exchange transfusion (ET), and the best time to apply IVIG remains unclear in the situations where hyperbilirubinaemia is severe (approaching or exceeding the ET threshold) or ET cannot be implemented. These guidelines are formulated with rigorous methods, but with the lower quality of evidence.
